Hebei Changshan Biochem Pharma (SHE:300255) — Market Cap & Net Worth
Market Cap & Net Worth: Hebei Changshan Biochem Pharma (300255)
Hebei Changshan Biochem Pharma (SHE:300255) has a market capitalization of $5.56 Billion (CN¥38.01 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #3342 globally and #500 in its home market, demonstrating a -0.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hebei Changshan Biochem Pharma's stock price CN¥41.36 by its total outstanding shares 919060878 (919.06 Million). Analyse 300255 cash flow conversion to see how efficiently the company converts income to cash.
Hebei Changshan Biochem Pharma Market Cap History: 2015 to 2026
Hebei Changshan Biochem Pharma's market capitalization history from 2015 to 2026. Data shows growth from $1.28 Billion to $5.56 Billion (14.92% CAGR).
Hebei Changshan Biochem Pharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hebei Changshan Biochem Pharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.61x
Hebei Changshan Biochem Pharma's market cap is 2.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.28 Billion | $915.99 Million | $156.30 Million | 1.40x | 8.20x |
| 2016 | $1.04 Billion | $1.12 Billion | $175.49 Million | 0.93x | 5.95x |
| 2017 | $838.35 Million | $1.42 Billion | $196.92 Million | 0.59x | 4.26x |
| 2018 | $543.84 Million | $1.65 Billion | $139.99 Million | 0.33x | 3.88x |
| 2019 | $726.27 Million | $2.07 Billion | $225.29 Million | 0.35x | 3.22x |
| 2020 | $826.79 Million | $2.36 Billion | $252.84 Million | 0.35x | 3.27x |
| 2021 | $1.09 Billion | $2.97 Billion | $233.57 Million | 0.37x | 4.66x |
| 2022 | $736.24 Million | $2.34 Billion | $17.51 Million | 0.32x | 42.04x |
| 2023 | $1.75 Billion | $1.41 Billion | -$1.24 Billion | 1.24x | N/A |
| 2024 | $2.69 Billion | $1.03 Billion | -$249.48 Million | 2.61x | N/A |
Competitor Companies of 300255 by Market Capitalization
Companies near Hebei Changshan Biochem Pharma in the global market cap rankings as of May 4, 2026.
Key companies related to Hebei Changshan Biochem Pharma by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Hebei Changshan Biochem Pharma Historical Marketcap From 2015 to 2026
Between 2015 and today, Hebei Changshan Biochem Pharma's market cap moved from $1.28 Billion to $ 5.56 Billion, with a yearly change of 14.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥5.56 Billion | -33.40% |
| 2025 | CN¥8.35 Billion | +210.66% |
| 2024 | CN¥2.69 Billion | +53.65% |
| 2023 | CN¥1.75 Billion | +137.65% |
| 2022 | CN¥736.24 Million | -32.31% |
| 2021 | CN¥1.09 Billion | +31.55% |
| 2020 | CN¥826.79 Million | +13.84% |
| 2019 | CN¥726.27 Million | +33.55% |
| 2018 | CN¥543.84 Million | -35.13% |
| 2017 | CN¥838.35 Million | -19.74% |
| 2016 | CN¥1.04 Billion | -18.52% |
| 2015 | CN¥1.28 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Hebei Changshan Biochem Pharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.56 Billion USD |
| MoneyControl | $5.56 Billion USD |
| MarketWatch | $5.56 Billion USD |
| marketcap.company | $5.56 Billion USD |
| Reuters | $5.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hebei Changshan Biochem Pharma
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. The company offers crude heparin sodium, heparin sodium API, heparin sodium injections, low molecular weight heparin calcium i… Read more